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P~rpose: The goal of this study was to determine the effects of vasopressin and the 
selective V2-receptor agonist desmopressin on human saphenous veins, with special 
emphasis on endothelium-mediated r sponses. 
Methods: Human saphenous vein segments were obtained from 35 patients undergoing 
coronary bypass urgery. Paired segments, one normal and the other deendothelized by 
gentle rubbing, were mounted for isometric recording of tension in organ baths. Con- 
centration-response curves to vasopressin and desmopressin were determined in the 
presence and in the absence of either the Vl-receptor antagonist d(CHz)sTyr(Me)AVI' 
(10 -6 mol/L),  the V1-V2-receptor antagonist desGly-d(CHz)sD-Tyr(Et)ValAVP (10 -0 
mol/L),  indomethacin (10 -6 mol/L),  or N~-nitro-L-arginine methyl ester hydrochlo- 
ride (L-NAME, 10 -4 mol/L).  
Results: In vein rings under resting tension, vasopressin produced concentration-depen- 
dent, endothelium-independent co ractions with a concentration ofvasopressin produc- 
ing half-maximal contractions (ECs0) of 3.44 × 10 -s mol/L.  The vasopressin V 1- 
receptor antagonist (10- 6 mol /L)  displaced the control curve to vasopressin 9.86-fold to 
the right in a parallel manner. In precontracted vein rings previously treated with the 
Vl-antagonist (10 -6 mol/L),  vasopressin caused endothelium-dependent relaxations. 
This relaxation was reduced significantly by indomethacin (10 -6 mol /L)  and unaffected 
by the V1-Vz-receptor antagonist (10 -6 tool/L) or by L-NAME (10 -4 mol/L).  Desmo- 
pressin caused endothelium-dependent r laxations in precontracted vein rings that were 
inhibited by the mixed V~-V2-receptor antagonist and by indomethacin, but not by the 
Vl-antagonist or by pretreatment with L-NAME. 
Conclusions: These observations indicate that vasopressin exerts contractile ffects on 
human saphenous vein by Vx-receptor stimulation. Vasopressin causes dilatation of 
human saphenous vein only ifV~-receptor blockade is present. This relaxation appears to 
be mediated by the release of relaxant prostaglandins, probably derived from endothelial 
cells, and is independent ofVz-receptor stimulation or release of nitric oxide. Desmopres- 
sin elicits relaxation that is largely dependent on Vz-receptor stimulation, which may 
bring about he release of dilating prostaglandins from the endothelial cells. (J Vasc Surg 
1997;25:696-703.) 
Vasopressin causes powerful constriction in a va- 
riety of vascular egions.l-3 The vasopressin receptor 
designated V1 seems to mediate the vasoconstrictor 
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action of the peptide, whereas its antidiuretic action 
is mediated through V2, cyclic adenosine mono- 
phosphate-dependent receptors. 46 With regard to 
human vessels, vasopressin causes Vl-mediated con- 
striction in isolated mesenteric arteries 7,s and in sub- 
mucosal arterioles of the intestinal microcirculafion. 9 
Further studies of  the physiologic effects ofvasopres- 
sin have suggested the existence of  V2-receptors in 
some vascular beds that could mediate vasodilata- 
fion. Administration of  either V2-agonists or vaso- 
pressin during V 1-receptor blockade increased blood 
flow in some vascular beds and decreased peripheral 
vascular resistance in both humans and dogs. 1°-12 
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Recent experiments suggest that the vasopressin-in- 
duced vasodilatation i  the human forearm is caused 
by release of nitric oxide mediated by V2-receptor 
stimulation, 13whereas in human isolated mesenteric 
and cerebral arteries the vasodilatation seems to be 
the result of release of dilating prostaglandins from 
the vessel wall. 8,~4 
To date, no information is available concerning 
the effects and pharmacologic receptors of vasopres- 
sin and desmopressin in human saphenous veins. The 
effects of vasopressin i  this vascular bed may be of 
physiologic and pathologic significance in those 
states characterized by an increased plasma vasopres- 
sin level, such as dehydration and exercise, as well as 
in some patients with hypertension or congestive 
heart failure.is 17 Moreover, the endothelial capacity 
for nitric oxide and prostacyclin production in re- 
sponse to vasopressin may have important implica- 
tions in understanding the pathophysiolog 9, of veins 
used as autologous grafts in the arterial circulation or 
in coronary artery bypass surgery. Accordingly, the 
objective of this investigation was to determine the 
effects of vasopressin and desmopressin human 
saphenous veins. Observations were made in the 
presence and absence ofendothelium, aswell as with 
vasopressin receptor antagonists and inhibitors of 
cyclooxygenase. 
METHODS 
Vein segments were taken from portions of hu- 
man saphenous veins of patients undergoing coro- 
nary artery bypass urgery for coronary artery disease 
(35 patients [29 men and six women; age range, 37 
to 76 years]). The study was approved by the ethical 
committee of our institution, and informed consent 
was obtained from each patient before the study. 
During surgical preparation of the saphenous vein, 
the dilation procedure was avoided. The veins were 
immediately placed in chilled Krebs-Henseleit solu- 
tion, and rings 3 mm long were cut for isometric 
recording of tension. The outside diameter of the 
rings was measured with an ocular micrometer 
within a Wild M8 zoom microscope (Heerbrugg, 
Switzerland) and ranged from 3.2 to 4 mm. In ap- 
proximately 50% of the vein rings, the endothelium 
was removed mechanically by insertion of a rough- 
ened stainless teel wire into the lumen and gently 
rolling the rings on wet filter paper. 
Two stainless steel pins 200 ~m in diameter were 
introduced through the lumen of the vein ring. One 
pin was fixed to the wall of the organ bath, and the 
other was connected to a force-displacement trans- 
ducer (Grass FT03). Changes in isometric force were 
recorded on a Grass polygraph (model 7). Each vein 
ring was set up in a 4 ml bath that contained modi- 
fied Krebs-Henseleit solution of the following milli- 
molar composition: sodium chloride, 115; potassium 
chloride, 4.6; magnesium chloride, 1.2; calcium 
chloride, 2.5; sodium bicarbonate, 25; glucose, 5; 
and disodium ethylenediaminetetraacetic acid, 0.01. 
The solution was equilibrated with 95% oxygen and 
5% carbon dioxide to give a pH of 7.3 to 7.4. Tem- 
perature was held at 37 ° C. To establish the resting 
tension for maximal force development, a series of 
preliminary experiments were performed on rubbed 
and unrubbed vein rings of similar length and outer 
diameter that were exposed repeatedly to 60 
mmol /L  potassium chloride. Basal tension was in- 
creased gradually until contractions were maximal. 
The optimal rest tension was 3 gin. The vein rings 
were allowed to attain a steady level of tension during 
a 2-hour accommodation period before testing. The 
contractile response to 60 mmol /L  potassium chlo- 
ride was similar in rubbed and unrubbed vein rings 
(5845 + 765 versus 6258 + 480 mg; p > 0.05). To 
study relaxation, vein tings were precontracted with 
10 -7  tO 3 X 10 -7 mol /L  norepinephrine, which 
gave a contraction ranging from 50% to 70% of 
contractions produced by 60 mmol /L  potassium 
chloride. 
Functional integrity of the endothelium was con- 
firmed routinely by the presence or absence of relax- 
ation induced by acetylcholine (10 -7 tO 10 -6 
tool/L) or substance P (10 -9 tool/L) during con- 
traction obtained with norepinephrine (10 -7 to 3 × 
10 -7 mol/L).  After each experiment the vein tings 
were carefully opened flat and stained with silver 
nitrate to visualize the endothelium. Only results 
from rings with more than 70% of the endothelium 
were considered to be control rings. Vessels in which 
the endothelium had been rubbed never showed 
more than 5% of their intima covered with endothe- 
lium. 
After the equilibration period, concentration-re- 
sponse curves for vasopressin (10 -9 tO 10 -6 mol/L)  
were obtained in paired rings under resting tension 
in the absence and presence of the Vl-antagonist 
d(CHz)sTyr(Me)AVP (10 6 mol/L).  To check the 
possibility that the V2-receptor agonist desmopressin 
is an antagonist of the Vl-receptor-mediated con- 
traction, the effects of vasopressin were evaluated in 
the presence of 10 -7 mol /L  desmopressin. 
To study vasopressin-induced relaxation, rings 
were incubated with the Vl-receptor antagonist 
d(CH 2)sTyr(Me)AVP (10 -6 tool/L) and then con- 
tracted with 10 7 to 3 x 10 -7 mol /L  norepineph- 
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Fig. 1. A, Concentration-response curves for vasopressin determined in human saphenous 
vein rings with (solid circles; n = 8) and without(open circles; n = 6) endothelium and in the 
presence of the Vl-antagonist d(CH2)sTyr(Me)AVP in rings with endothelium (open squares; 
10 6 mol/L; n = 6). B, Contractile ffects of potassium chloride (KCI, 60 mmol/L; n = 10), 
norepinephrine (10 -6 mol/L; n = 6), and vasopressin (10 6 mol/L; n = 8). Results are 
expressed as a percentage of the contraction developed by 60 mmol/L potassium chloride by 
each preparation. Values are means Z SEM. 
fine. After a stable contraction was obtained, concen- 
tration-response curves to vasopressin (10-11 to 3 × 
10 7 tool/L)  were determined in paired rings in the 
absence and presence of either the V 1-V2-receptor 
antagonist desGly-d(CH2)sD-Tyr(Et)ValAVP (10 6 
mol /L) ,  indomethacin (10 -6 tool/L),  or NG-nitro -
L-arginine methyl ester hydrochloride (L-NAME; 
10 4 tool/L).  Concentration-response curves to the 
V2-agonist desmopressin (10 la to 3 × 10 -7 
mol /L)  were also determined from a group of pre- 
contracted tings in the absence and in the presence of 
either the mixed V1-V2-antagonist (10 6 tool /L)  or 
indomethacin (10 -6 tool/L).  As a control for each 
experimental group, vein rings were contracted in a 
way similar to that described above and left untreated 
(without desmopressin orvasopressin addition to the 
bath). In these vein rings, less than 10% variability in 
tension below or above the elevated tension was 
observed throughout the experiment. 
Antagonists were added to the organ bath cham- 
bers 15 minutes before the initiation of cumulative 
concentration-response curves to agonists. Only one 
concentration-response curve to vasopressin or des- 
mopressin was made in each vein ring. 
Drugs. The following drugs were used: norepi- 
nephrine hydrochloride, acetylcholine chloride, L- 
NAME, arginine vasopressin acetate salt, deamino-Cys 
D-arginine vasopressin acetate salt (desmopressin), 
d(CH2)sTyr(Me)AVP [(1-([3-mercapto-[3,[3-cyclopen- 
tamethylenepropionic a id) 2-(O-methyl)-tyrosine, 
8-arginine) vasopressin], desGly-d(CH2)sD-Ty- 
r(Et)ValAVP [ (1-([3-mercapto-J3,[3-cyclopentamethyl- 
enepropionic acid) 2-(O-ethyl)-D-tyrosine, 4-valine, 
8-arginine, 9-desglycine) vasopressin], substance P ace- 
tate salt and sodium nitroprusside dihydrate (Sigma 
Chemical Co., St. Louis, Mo.). 
Drugs were prepared and diluted in distilled wa- 
ter, except for indomethacin. Indomethacin was dis- 
solved in absolute ethanol and sodium bicarbonate 
solution (150 retool/L) and readjusted to a pH of  
7.4 with hydrochloric acid before use. Fresh stock 
solutions of the drugs were prepared every day. 
Data analysis. Values for concentrations ofva- 
sopressin producing half-maximal contractions 
(EC50) were determined from individual concen- 
tration-response curves by nonlinear regression 
analysis; the geometric means were calculated from 
these values. Relaxation was expressed as a per- 
centage of  the norepinephrine-induced contrac- 
tion. All values are expressed as mean + SEM. In 
each experimental group, n indicates the number 
of  patients. At least eight vein rings were obtained 
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from each patient. Differences between agonist- 
and antagonist-treated groups were assessed by 
one-way analysis of variance. Differences between 
means were identified by t test. Statistical signifi- 
cance was accepted at p < 0.05. 
RESULTS 
Effects ofvasopressin vein rings under rest- 
ing tension. Vasopressin (10  -9  tO 10 -6 mol/L)  
caused concentration-dependent co ractions, with 
an EC~0 of 3.44 × 10 -8 mol/L.  These contractions 
were endothelium-independent (Fig. 1, A). The 
maximum tensions developed were significantly less 
than those produced by potassium chloride (60 
mmol/L)  or norepinephrine (3 × 10 -6 tool/L) in 
the same preparations (Fig. 1, B). ECs0 values fbr 
vasopressin i  saphenous veins are of a magnitude 
greater than those obtained in human arteries from 
different vascular beds (7.2 x 10 ~0 mol /L  and 
5.9 × 10 -l° mol /L  for human cerebral and mesen- 
teric arteries respectively). 8,~4 The concentration- 
response curves to vasopressin were of the same mag- 
nitude in veins with or without endothelium 
(Fig. 1, A). The presence of the Vl-antagonist 
d(CH2)sTyr(Me)AVP (10 6 mol/L)  in the organ 
bath displaced the control curve tbr vasopressin 
9.86-fold (p < 0.05) to the right in a parallel manner 
(ECso , 3.39 × 10 .7 tool/L), but differences in the 
maximal tensions developed were not significant 
(p > 0.05). 
Effects of  vasopressin in precontracted rings. 
To determine whether vasopressin duces relaxation 
in precontractcd veins, increasing concentrations of
this pcptide were added to rings during submaximal 
contraction i duced by norepinephrine ( 10 -7 to 3 × 
10 7 mol/L).  Fig. 2 shows that vasopressin caused 
further contractions in precontracted arteries with 
and without endothelium. In these rings the abili~ 
of the smooth muscle to relax was tested by adding 
10 -7 mol /L  sodium nitroprusside when the maximal 
contractions had been attained with vasopressin. Un- 
der these conditions sodium nitroprusside caused 
almost complete relaxation of both normal and en- 
dothelium-denudcd rings. 
When the vein rings were pretreated with the 
W-receptor antagonist d(CH2)sTyr(Me)AVP (10 _6 
tool/L) to prevent vasoprcssin-induced constriction 
and when they were contracted with norepinephrine 
(10  -7  tO 3 × 10  7 mol/L) ,  vasopressin (10 -~l to 
3 X 10  _7 mol/L)  produced concentration-depen- 
dent relaxations that were greater (p < 0.05) in veins 
with endothelium than in endothclium-denuded 
rings (Fig. 3, A). The mixed V1-V2-receptor an- 
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Fig. 2. Contractile effects of vasopressin i  saphenous 
vein rings with and without endothelium previously con- 
tracted with norepinephrine (NE, 10 -7 tool/L). Sodium 
nitroprussidc (SNP, 10 -5 tool/L) caused almost complete 
relaxation of vein rings. 
tagonist desGly-d(CH2)sD-Tyr(Et)ValAVP (10 -6 
mol/L)  had no effect on vasopressin-induced r lax- 
ation (Fig. 3, B). However, the presence of indo- 
methacin (10 -6 mol/L)  significantly (p < 0.05) re- 
duced the relaxation induced by vasopressin (Fig. 3, 
B). On the other hand, L-NAME (10 -4 mol/L)  
treatment had no erect on vasopressin-induced r - 
laxation (Fig. 3, B). The same concentration of L- 
NAME abolished completely the relaxations to ace- 
tvlcholine (10 -7 to 10 -6 mol/L)  in vein rings with 
endothelium. 
Effects of  desmopressin. The selective antidi- 
urctic agonist desmopressin (10 11 to 3 × 10 7 
mol/L)  did not produce significant changes in the 
resting tension of saphenous veins with (n = 4) or 
without (n = 4) endothelium. In addition, the pres- 
ence of desmopressin (10 -7 mol/L)  did not affect 
the concentration-response curve to vasopressin (re- 
suits not shown). In veins contracted with norepi- 
nephrinc (10 7 to 3 x 10 -7 mol/L),  desmopressin 
caused concentration-dependent relaxations that 
were greater (p < 0.05) in segments with endothelium 
than in endothclium-denudcd tings (Fig. 4, A). The 
specific Vl-receptor antagonist d(CH2)sTyr(Me)AVP 
(10  -6  mol/L)  did not have a significant effect on 
desmopressin-induced r laxations (Fig. 4, A). In 
contrast, the V1-V2-receptor antagonist desGly- 
d(CH2)sD-Tyr(Et)ValAVP (10 6 tool/L) signifi- 
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Fig. 3. Relaxation to vasopressin of vein rings previously treated with the antagonist 
d(CH2)sTyr(Me)AVP (10 -6 tool/L) and contracted with norepinephrine (10 7 to 3 x 10 -7 
mol/L). A, Concentration-response curves in the presence (solid circles; n = 8) and absence 
(open circles; n = 8) of endothelium. B, Relaxation to vasopressin rings with endothelium in 
the absence ofindomethacin (solid circles) and presence ofindomethacin (open triangles; 10 -6 
tool/L; n = 7) or NG-nitro-L-arginine methyl ester hydrochloride (open squares; 10 -4 mol/L; 
n = 6) and in the presence of the vt-g2-antagonist desGly-d(CH2)sD-Tyr(Et)ValAVP (solid 
squares; 10 6 mol/L; n = 4). Values are means + SEM. 
candy reduced desmopressin-mediated r laxation 
(p < 0.05; Fig. 4, A). The presence ofindomethacin 
(10 -6 mol /L)  but not L-NAME (10 -4 tool /L)  sig- 
nificantly (p < 0.05) reduced the relaxation induced 
by desmopressin (Fig. 4, B). 
D ISCUSSION 
Our results show that vasopressin exerts relatively 
low contractile ffects (compared with potassium chlo- 
ride depolarization rct-adrenergic stimulation) on hu- 
man saphenous veins. The low potency ofvasopressin- 
expressed in terms of EC~0 values-and the low 
magnitude of its maximal effects were features consis- 
tently observed in these experiments, indicating that, 
compared with human arteries, these veins may have a 
low population or sensitivity of receptor sites for this 
peptide. 8,14 The low responsiveness of saphenous veins 
to vasopressin does not reflect a nonspecific effect or an 
effect caused by the state of the preparation because 
considerably higher contractions were obtained with 
norepinephrine and potassium chloride. The V 1-antag- 
onist d(CH2)~Tyr(Me)AVP produced a 9.86-fold 
shift to the right of the control concentration-re- 
sponse curve to vasopressin, presumably because of 
an equilibrium competitive agonist-antagonist inter- 
action. The same concentration of the antagonist 
produced a 1250- and 1525-fold shift in human 
cerebral and mesenteric arteries, respectively, s,14 
values greater than that obtained in the present 
study. It seems likely that the properties of  the 
vasopressin receptor of  human saphenous veins 
that determine the affinity for a common antago- 
nist are lower than those of  the corresponding 
receptors in human arteries. 
Our data also show that the vasopressin-induced 
contraction is not linked to the presence of an intact 
endothelium, indicating that vasodilator substances 
secreted by endothelial cells under basal spontaneous 
conditions 18 do not counteract the contractile ffects 
ofvasopressin on smooth muscle cells. Maximal con- 
tractions to 60 mmol /L  potassium chloride did not 
differ between rubbed and unrubbed veins, which 
suggests that a change in the mechanical properties 
of the vessel wall caused by endothelium removal 
does not play an important role on reactivity of 
rubbed veins. In agreement with the results of this 
study, previous experiments have shown that vaso- 
pressin causes endothelium-independent contrac- 
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(open triangles; 10 -6 tool/L; n = 7) or NG-nitro-L-arginine methyl ester hydrochloride (open 
squares; 10 -4 mol/L; n = 6). Values are means + SEM. 
tions in human mesenteric, s cerebral, 19 and uterine 2° 
arteries. Therefore it is most likely that the contrac- 
tile effects of vasopressin on human saphenous veins 
are caused by direct stimulation of specific receptors 
located on smooth muscle cells. 
Studies in healthy subjects have shown that the 
effects of  vasopressin on human forearm blood 
flow-as measured by venous occlusion plethysmogra- 
phy-are biphasic. 21,22 The lower doses ofvasopressin 
(<0.1 ng/kg per minute) caused vasoconstriction, 
whereas the higher doses (>0.5 ng/kg per minute) 
caused vasodilation. In one study it was observed 
that vasopressin produced adecrease in digital blood 
flow together with forearm vasodilation. 12 In our 
experiments in human saphenous veins, we have ob- 
served only constriction in response to vasopressin, 
even when the arterial segments were precontracted 
with norepinephrine. Therefore it appears that, un- 
der the present in vitro conditions, Vl-mediated con- 
traction is the predominant effect in response to 
vasopressin. 
The results obtained in contracted veins show 
that vasopressin elicits concentration-dependent r - 
laxation only if Vl-receptor blockade is present. In 
addition, these results show that desmopressin, a 
highly specific antidiuretic V2-receptor agonist, 23 in- 
duced concentration-dependent r laxation similar to 
that observed in response to the combination of 
vasopressin plus the Vl-antagonist. In contrast to the 
results described here, no evidence for the presence 
of V2-receptor-mediated dilatation was obtained af- 
ter application of  vasopressin or desmopressin to 
isolated submucosal rterioles of  the intestinal circu- 
lation of guinea pigs, rabbits, and humans. 9 In addi- 
tion to regional differences, it is possible that the size 
of the vessels used may be a factor in the response to 
desmopressin, as previously reported for vasopres- 
sin.24, 2s 
Until now the possibility that vasopressin and 
desmopressin may dilate human veins through 
V2-receptors has not been investigated. We used 
the mixed V1-V2-vasopressin antagonist desGly- 
d(CH2)sD-Tyr(Et)ValAVP because it appears to be 
the most potent in vitro antagonist of human vaso- 
pressin-stimulated renal adenylate cyc lasef i  6 It also 
antagonizes exogenous vasopressin-stimulated an-
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tidiuresis in conscious water-loaded rats. 27 From a 
theoretical point of view, this analog would be a 
highly potent specific vascular V2-antagonist. In the 
present experiments, the mixed V~-V2-antagonist 
desGly-d(CH2)sD-Tyr(Et)ValAVP prevented the re- 
laxation induced by desmopressin, whereas the V 1- 
antagonist d(CH2)~Tyr(Me)AVP did not. These re- 
suits suggest that the relaxation observed in response to 
desmopressin is endothelium-dependent and mediated 
by a receptor similar to the renal V2-receptor , afinding 
similar to that previously reported in dogs 28"29 and in 
isolated human arteries. 8,14 In addition, treatment with 
indomethacin, but not L-NAME, inhibited the desmo- 
pressin-induced relaxation, suggesting that dcsmopres- 
sin stimulates the release of vasodilator prostaglandins 
from endothelial cells. Derkx et al.30 reported that des- 
mopressin caused adecrease in diastolic blood pressure 
and an increase in heart rate in healthy vohmteers. They 
suggested that the vasodilating properties of desmo- 
pressin were caused by competitive antagonism of en- 
dogenous vasopressin on vascular V 1-receptors. How- 
ever, similar hemodynamic effects of desmopressha 
administration have been described in patients with 
central diabetes insipidus, who lack endogenous vaso- 
pressin, n,3~ In the present experiments and in those 
of Johns 32 in aorta and pulmonary arteries from rab- 
bits and rats, desmopressin caused dilation in the 
absence ofvasopressin and in the presence of a selec- 
tive Vl-antagonist. Furthermore, our experiments 
show that desmopressin did not affect he contractile 
responses to vasopressin. Therefore it is doubtful that 
the vasodilating action of desmopressin could be 
caused by competitive antagonism of the Vl-medi- 
ated vasoconstriction. It is more likely that these 
effects are caused by Vz-receptor activation. 
In contrast, the V1-V2-antagonist desGly- 
d(CH2)sD-Tyr(Et)ValAVP did not show a signifi- 
cant effect on vasopressin-induced r laxation. There- 
fore it seems unlikely that the relaxant action of 
vasopressin on human saphenous veins is mediated 
by classic V2-receptors. The reasoias for this unex- 
pected finding are not currently known. The V 1-V 2- 
antagonist desGly-d(CH2)sD-Tyr(Et)ValAVP exerts 
potent antagonistic effects on vascular contraction 
mediated through V 1-receptors. s Consequently, it is 
not established at present what side effects might 
result from the blockade of Vl-receptors. Before we 
can rule out the intervention of V2-receptors in the 
vasopressin-induced r laxation, it would seem to be 
necessary to design V2-antagonists that would not 
block the Vl-receptors. On the other hand, the ef- 
fects ofvasopressin could be indirect, resulting from 
the release of mediator(s ) that induce dilatation. 
Among the potential mechanisms that could account 
for the dilatation in response to vasopressin, we have 
taken into consideration the possible intervention of 
the endothelial cell layer and the release of prosta- 
glandins. 
The vasopressin-induced dilatation after Vl-re- 
ceptor blockade depends on the presence of an intact 
cndothelium because it was absent in arteries de- 
nuded of endothelium. However, this endothelium- 
dependent relaxation does not involve the interven- 
tion of the L-arginine-nitric oxide pathway because 
L-NAME, a selective inhibitor of nitric oxide syn- 
thase, did not inhibit the vasopressin-induced r lax- 
ation. Because vasopressin stimulates the synthesis of 
prostaglandin 12 by blood vessels, 33 it might be ex- 
pected that cyclooxygenase inhibitors can modulate 
the responses to vasopressin. Our results show that 
indomethacin inhibits the relaxant effects of vaso- 
pressin. This strongly suggests that the effect is 
largely caused by the release o f  vas0dilator prosta- 
glandins from the endothelial cell layer. 
In summary, our study shows that vasopressin 
and desmopressin dilate human saphenous veins 
through different mechanisms. The integrity of the 
endothelium seems to be essential to the observation 
of this effect. However, the endothelium-dependent 
relaxation to these peptides does not involve the 
intervention of the L-arginine-nitric oxide pathway. 
The vasopressin-induced r laxation requires previous 
blockade ofVl-receptors , appears to be mediated by 
the release of relaxant prostaglandins, is probably 
derived from endothelial cells, and is independent of
V2-receptor stimulation or nitric oxide formation. 
The effect of  desmopressin s largely dependent on 
stimulation of Vz-receptors, which may bring about 
the release of dilating prostaglandins from the endo- 
thelial cell layer. 
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